Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial

Objectives. The aim of this study was to use neurofeedback (NF) training as the add-on therapy in patients with schizophrenia to improve their clinical, cognitive, and psychosocial condition. The study, thanks to the monitoring of various conditions, quantitative electroencephalogram (QEEG) and brai...

Full description

Bibliographic Details
Main Authors: Renata Markiewicz, Agnieszka Markiewicz-Gospodarek, Beata Dobrowolska, Bartosz Łoza
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Neural Plasticity
Online Access:http://dx.doi.org/10.1155/2021/4488664
id doaj-79ba68dea76c4d7eb6c3ea482390aa3e
record_format Article
spelling doaj-79ba68dea76c4d7eb6c3ea482390aa3e2021-08-23T01:32:24ZengHindawi LimitedNeural Plasticity1687-54432021-01-01202110.1155/2021/4488664Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control TrialRenata Markiewicz0Agnieszka Markiewicz-Gospodarek1Beata Dobrowolska2Bartosz Łoza3Psychiatric Nursing DepartmentDepartment of Human AnatomyDepartment of Management in NursingDepartment of PsychiatryObjectives. The aim of this study was to use neurofeedback (NF) training as the add-on therapy in patients with schizophrenia to improve their clinical, cognitive, and psychosocial condition. The study, thanks to the monitoring of various conditions, quantitative electroencephalogram (QEEG) and brain-derived neurotrophic factor (BDNF), was supposed to give an insight into mechanisms underlying NF training results. Methods. Forty-four male patients with schizophrenia, currently in a stable, incomplete remission, were recruited into two, 3-month rehabilitation programs, with standard rehabilitation as a control group (R) or with add-on NF training (NF). Pre- and posttherapy primary outcomes were compared: clinical (Positive and Negative Syndrome Scale (PANSS)), cognitive (Color Trails Test (CTT), d2 test), psychosocial functioning (General Self-Efficacy Scale (GSES), Beck Cognitive Insight Scale (BCIS), and Acceptance of Illness Scale (AIS)), quantitative electroencephalogram (QEEG), auditory event-related potentials (ERPs), and serum level of BDNF. Results. Both groups R and NF improved significantly in clinical ratings (Positive and Negative Syndrome Scale (PANSS)). In-between analyses unveiled some advantages of add-on NF therapy over standard rehabilitation. GSES scores improved significantly, giving the NF group of patients greater ability to cope with stressful or difficult social demands. Also, the serum-level BDNF increased significantly more in the NF group. Post hoc analyses indicated the possibility of creating a separate PANSS subsyndrome, specifically related to cognitive, psychosocial, and BDNF effects of NF therapy. Conclusions. Neurofeedback can be effectively used as the add-on therapy in schizophrenia rehabilitation programs. The method requires further research regarding its clinical specificity and understanding mechanisms of action.http://dx.doi.org/10.1155/2021/4488664
collection DOAJ
language English
format Article
sources DOAJ
author Renata Markiewicz
Agnieszka Markiewicz-Gospodarek
Beata Dobrowolska
Bartosz Łoza
spellingShingle Renata Markiewicz
Agnieszka Markiewicz-Gospodarek
Beata Dobrowolska
Bartosz Łoza
Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial
Neural Plasticity
author_facet Renata Markiewicz
Agnieszka Markiewicz-Gospodarek
Beata Dobrowolska
Bartosz Łoza
author_sort Renata Markiewicz
title Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial
title_short Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial
title_full Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial
title_fullStr Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial
title_full_unstemmed Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial
title_sort improving clinical, cognitive, and psychosocial dysfunctions in patients with schizophrenia: a neurofeedback randomized control trial
publisher Hindawi Limited
series Neural Plasticity
issn 1687-5443
publishDate 2021-01-01
description Objectives. The aim of this study was to use neurofeedback (NF) training as the add-on therapy in patients with schizophrenia to improve their clinical, cognitive, and psychosocial condition. The study, thanks to the monitoring of various conditions, quantitative electroencephalogram (QEEG) and brain-derived neurotrophic factor (BDNF), was supposed to give an insight into mechanisms underlying NF training results. Methods. Forty-four male patients with schizophrenia, currently in a stable, incomplete remission, were recruited into two, 3-month rehabilitation programs, with standard rehabilitation as a control group (R) or with add-on NF training (NF). Pre- and posttherapy primary outcomes were compared: clinical (Positive and Negative Syndrome Scale (PANSS)), cognitive (Color Trails Test (CTT), d2 test), psychosocial functioning (General Self-Efficacy Scale (GSES), Beck Cognitive Insight Scale (BCIS), and Acceptance of Illness Scale (AIS)), quantitative electroencephalogram (QEEG), auditory event-related potentials (ERPs), and serum level of BDNF. Results. Both groups R and NF improved significantly in clinical ratings (Positive and Negative Syndrome Scale (PANSS)). In-between analyses unveiled some advantages of add-on NF therapy over standard rehabilitation. GSES scores improved significantly, giving the NF group of patients greater ability to cope with stressful or difficult social demands. Also, the serum-level BDNF increased significantly more in the NF group. Post hoc analyses indicated the possibility of creating a separate PANSS subsyndrome, specifically related to cognitive, psychosocial, and BDNF effects of NF therapy. Conclusions. Neurofeedback can be effectively used as the add-on therapy in schizophrenia rehabilitation programs. The method requires further research regarding its clinical specificity and understanding mechanisms of action.
url http://dx.doi.org/10.1155/2021/4488664
work_keys_str_mv AT renatamarkiewicz improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial
AT agnieszkamarkiewiczgospodarek improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial
AT beatadobrowolska improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial
AT bartoszłoza improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial
_version_ 1721199031185571840